Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOGGIC/FIREFLY-2: Tovorafenib Monotherapy vs Standard Chemotherapy in Pediatric Low-Grade Glioma with RAF Alterations
2024-510742-13-00Phase 3Authorised
- Sponsor
- Day One Biopharmaceuticals
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 27
01
Overview
Phase 3, randomised trial in low-grade glioma (LGG), glioma and Glioneuronal Neoplasm comparing Tovorafenib monotherapy with Standard of care chemotherapy (2 arms). Primary endpoint: Objective response rate (ORR) per RAPNO. Planned start Oct 2024; status: authorised.
02
Drugs
tovorafenib
03
Conditions
low-grade glioma (LGG)gliomaGlioneuronal Neoplasm
Beyond the preview
Go deeper on 2024-510742-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510742-13-00.